OmniAb, Inc. (OABI)
NASDAQ: OABI · Real-Time Price · USD
2.345
-0.035 (-1.47%)
Jun 11, 2026, 2:37 PM EDT - Market open
OmniAb Revenue
OmniAb had revenue of $14.43M in the quarter ending March 31, 2026, with 247.30% growth. This brings the company's revenue in the last twelve months to $28.94M, up 8.21% year-over-year. In the year 2025, OmniAb had annual revenue of $18.67M, down -29.27%.
Revenue (ttm)
$28.94M
Revenue Growth
+8.21%
P/S Ratio
11.82
Revenue / Employee
$325,157
Employees
89
Market Cap
339.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.67M | -7.73M | -29.27% |
| Dec 31, 2024 | 26.39M | -7.77M | -22.75% |
| Dec 31, 2023 | 34.16M | -24.91M | -42.17% |
| Dec 31, 2022 | 59.08M | 24.33M | 70.02% |
| Dec 31, 2021 | 34.75M | 11.48M | 49.34% |
| Dec 31, 2020 | 23.27M | 4.95M | 27.02% |
| Dec 31, 2019 | 18.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| REGENXBIO | 87.82M |
| Enanta Pharmaceuticals | 69.21M |
| Verastem | 49.59M |
| X4 Pharmaceuticals | 9.01M |
| Artiva Biotherapeutics | 251.00K |
OABI News
- 4 weeks ago - OmniAb reports Q1 EPS (6c), consensus (10c) - TheFly
- 4 weeks ago - OmniAb raises FY26 revenue view to $28M-$33M, consensus $28.0M - TheFly
- 4 weeks ago - OmniAb Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - OmniAb Slides: Q1 2026 - Filings
- 4 weeks ago - OmniAb Earnings release: Q1 2026 - Filings
- 4 weeks ago - OmniAb Quarterly report: Q1 2026 - Filings
- 4 weeks ago - OmniAb Reports First Quarter 2026 Financial Results and Business Highlights - Business Wire
- 6 weeks ago - OmniAb Proxy statement: Proxy filing - Filings